Visualizing cancer in a different light
NX Development Corp. (NXDC) Receives FDA Orphan-Drug Designation for Gleolan® (aminolevulinic acid HCl) in Meningioma
Lexington, KY, Jan. 12, 2021 (GLOBE NEWSWIRE) — NX Development Corp. (NXDC), a life sciences company wholly owned by photonamic GmbH & Co. KG., today announced FDA orphan-drug designation for Gleolan, an optical imaging agent for the visualization of tumor tissue in patients undergoing surgical resection for meningioma.
NX DEVELOPMENT CORP. (NXDC) LAUNCHES GLEOLAN™ (AMINOLEVULINIC ACID HCL) MENINGIOMA PHASE III CLINICAL TRIAL (NXDC-MEN-301)
“We are pleased to initiate this landmark study evaluating the utility of fluorescence-guided surgery (FGS) in the meningioma patient population. We are excited about the execution of this important study as we continue to expand the use of Gleolan in cancer surgeries around the world,” said Alan M. Ezrin, Ph.D.,…
Lexington-Based NX Development Corp (NXDC) Announces Baptist Health Lexington is First Hospital in Kentucky to Use Breakthrough Imaging Agent for Brain Tumor Visualization
Dr. Christian Ramsey first neurosurgeon in state to use GleolanTM for enhanced visualization of high-grade gliomas/glioblastoma
NX Development Corp. (NXDC) Launches FDA-Approved Gleolan™ (aminolevulinic acid HCl) for Enhanced Visualization of High-Grade Gliomas (including Glioblastomas)
NX Development Corp. (NXDC) Launches FDA-Approved GleolanTM (aminolevulinic acid HCl) for Enhanced Visualization of High-Grade Gliomas (including Glioblastomas).
NX Development Corp (NXDC) Announces Merger Acquisition by photonamic GmbH & Co. KG, a German Biotech Firm Engaged in 5-ALA-Related Pharmaceutical Business in Europe
NX Development Corp (NXDC), a privately-held life sciences company, today announced a Merger Acquisition as a result of which NXDC has become a wholly-owned subsidiary of photonamic GmbH & Co. KG